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abstract
PURPOSE Fear of cancer recurrence (FCR) is a signiﬁcantly distressing problem that affects a substantial number
of patients with and survivors of cancer; however, the overall efﬁcacy of available psychological interventions on
FCR remains unknown. We therefore evaluated this in the present systematic review and meta-analysis.
METHODS We searched key electronic databases to identify trials that evaluated the effect of psychological
interventions on FCR among patients with and survivors of cancer. Controlled trials were subjected to meta-
analysis, and the moderating inﬂuence of study characteristics on the effect were examined. Overall quality of
evidence was evaluated using the GRADE system. Open trials were narratively reviewed to explore ongoing
developments in the ﬁeld (PROSPERO registration no.: CRD42017076514).
RESULTS A total of 23 controlled trials (21 randomized controlled trials) and nine open trials were included. Small
effects (Hedges’s g) were found both at postintervention (g = 0.33; 95%CI, 0.20 to 0.46; P, .001) and at follow-
up (g = 0.28; 95% CI, 0.17 to 0.40; P, .001). Effects at postintervention of contemporary cognitive behavioral
therapies (CBTs; g = 0.42) were larger than those of traditional CBTs (g = 0.24; b = .22; 95% CI, .04 to .41; P =
.018). At follow-up, larger effects were associated with shorter time to follow-up (b = 2.01; 95% CI, 2.01 to
2.00; P = .027) and group-based formats (b = .18; 95% CI, .01 to .36; P = .041). A GRADE evaluation indicated
evidence of moderate strength for effects of psychological intervention for FCR.
CONCLUSION Psychological interventions for FCR revealed a small but robust effect at postintervention, which
was largely maintained at follow-up. Larger postintervention effects were found for contemporary CBTs that were
focused on processes of cognition—for example, worry, rumination, and attentional bias—rather than the
content, and aimed to change the way in which the individual relates to his or her inner experiences. Future trials
could investigate how to further optimize and tailor interventions to individual patients’ FCR presentation.
J Clin Oncol 37. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Despite improved treatments and prognoses, many
survivors of cancer face the possibility that their cancer
may return. For some, uncertainty leads to high levels
of fear of cancer recurrence (FCR), which is deﬁned as
the “fear, worry, or concern about cancer returning or
progressing.”1(p424) Individuals with active disease may
fear that stable disease will progress, and survivors of
cancer have been found to fear recurrence after
completion of active treatment.2 Such fears and
worries can thus be present from the beginning of
diagnosis and continue throughout treatment and the
survivorship trajectory. It is common to experience
some degree of FCR, and transitory or low levels of
FCRmay even be adaptive, alerting the patient to signs
of new or recurring cancer and encouraging positive
health behaviors.3,4 Persistent and excessive fear,
however, can be highly debilitating.1,2,5
FCR is among the most commonly reported concerns
by survivors of cancer and often their most frequently
endorsed unmet need.6 A comprehensive review2 es-
timates that, across different cancers, 22% to 87% of
survivors of cancer report moderate to high FCR, and
0% to 15% report high or clinical levels of FCR, al-
though there currently is no agreed upon clinical cutoff.
Furthermore, FCR seems to remain relatively stable over
time.2,7 Associations have been reported between FCR
and depression, poorer quality of life, and impaired
functioning,4,8 and a growing body of evidence suggests
that people with high FCR may both overuse health
services and avoid appropriate tests to identify re-
currence in a timely fashion.9 These results emphasize
the need for effective, evidence-based treatments
for FCR.
Interventions for FCR are emerging and the number
of randomized controlled trials (RCTs) that have
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evaluated such interventions is expanding rapidly. A recent
review10 identiﬁed ﬁve RCTs of FCR interventions that were
published in 2016 and 2017 alone, and several study
protocols and feasibility studies have been published
during this period.11-18 The exact number of existing psy-
chological interventions for FCR has not been systemati-
cally identiﬁed, and little is known about their efﬁcacy in
alleviating FCR symptoms. Thus far, only one meta-
analytical evaluation of the effect of mind–body inter-
ventions on FCR and cancer-related uncertainty in 19
RCTs has been published,19 which reported a small effect
both at postintervention (Hedges’s g = 20.36; P , .001)
and at follow-up (g =20.31; P, .001). However, this study
included not only psychological interventions, but also
physical interventions—for example, yoga or dance. Sec-
ond, only 13 of the 19 studies included an FCR-speciﬁc
measure, with the remaining studies assessing more
general cancer-related uncertainty. Although cancer-
related uncertainty overlaps with FCR,20-23 uncertainty
does not necessarily pertain to the perceived risk of re-
currence or progression, but can also relate to other issues
that are associated with cancer diagnosis and treatment,
including work-related issues or symptom management.
Third, potentially important between-study differences
remained unexplored in the former review,19 including the
type of psychotherapeutic framework and whether the
intervention speciﬁcally targeted FCR. Finally, the number
of FCR interventions being developed and evaluated is
rapidly expanding, and not all relevant studies were in-
cluded in the former review. Taken together, attempts to
synthesize the literature on psychological interventions for
FCR are limited, and an up-to-date review of current de-
velopments in the ﬁeld is lacking.1
The primary objective of the current study was to conduct
a systematic review and meta-analysis of the efﬁcacy of
psychological interventions for alleviating FCR among pa-
tients with and survivors of cancer as evaluated in controlled
trials. We hypothesized that psychological interventions are
efﬁcacious in reducing FCR symptoms. A secondary aim
was to explore the possible inﬂuence of between-study
differences in psychotherapeutic framework, treatment
format, intervention dose, cancer type, patient characteris-
tics, study design, and risk of bias. Finally, to explore current
developments in the ﬁeld, we aimed to conduct a narrative
evaluation of open trials (OTs) and noninferiority trials.
METHODS
The current study was conducted in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines and was preregistered
with PROSPERO (registration no.: CRD42017076514).25
Search Strategy
We conducted keyword-based searches in PubMed, Psy-
cINFO, Cochrane, CINAHL, and Embase databases. Keywords
related to cancer (eg, neoplasm or oncology) were combined
with keywords related to intervention (eg, psychotherap* or
“cognitive-behav* therap*” or “psychol* treatment”) and
terms related to fear (anxiet* or worr* or fear* or concern)
and recurrence (relapse or recur* or progress*). The full
search string is shown in the Data Supplement. Searches
were conducted for the period from the earliest time available
until June 2018, together with backward searches (snow-
balling) of reference lists of identiﬁed articles and earlier
systematic reviews and forward searches (citation tracking).
Selection Procedure and Data Extraction
English language reports published in peer-reviewed
sources were included. We assessed study eligibility us-
ing the PICO approach (population, intervention, com-
parison, and outcome).26
Population: adult patients with or survivors of cancer (age
18 years or older). Studies of children and adolescents
with cancer, patients without current cancer or
a cancer history, or caregivers of patients with cancer
were excluded.
Intervention: any psychological intervention that con-
sisted primarily (. 50%) of psychological methods—
for example, cognitive-behavioral, psycho-educative,
imagery-based, and meditative approaches. In-
terventions that involved physical approaches—for
example, yoga or exercise—could be included in the
intervention but only if they were a secondary com-
ponent (, 50%). Interventions were not required to
directly target FCR.
Comparison: Eligible studies were required to use
a control group—for example, waitlist, treatment as
usual, or attention/active control. Case studies, studies
that included only two active psychological in-
terventions and no control group (eg, noninferiority
trials), and open trials that employed uncontrolled
pre–post designs were excluded from the meta-
analysis. OTs, however, were included in the narra-
tive systematic review.
Outcome: pre- and postintervention data, or pre–post
change score data on one or more quantitative FCR-
relevant construct. FCR could be both primary and
secondary outcome. Only measures that pertained to
concerns about the return or progression of cancer
were included. Studies that used qualitative assess-
ments, quantitative measures at one time point only,
or only measures of general anxiety or worry were
excluded. Studies needed to report results as either
pre–post means and standard deviation/SE in all
groups, change scores in all groups, effect sizes (ESs;
eg, Cohen’s d or eta2), or provide other data that could
be converted to an ES.
One author removed duplicates (A.B.S.) and ﬁve authors
(N.M.T., J.G., A.B.S., B.T., and S.S.) took turns in pairs,
each screening one third of the records and ensuring that
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all records were independently evaluated by two authors.
Full texts of the remaining references were evaluated and
reasons for exclusion registered (Data Supplement). Dis-
agreements were discussed with a third author (N.M.T.,
B.T., or S.S.) until a negotiated conclusion was reached.
Data were extracted by one author (N.M.T.) and checked
by another author (C.M.). Studies were coded according to
a priori–speciﬁed characteristics, including study, in-
tervention, participant characteristics, and risk of bias.
Computing ESs
Hedges’s g, a variation of Cohen’s d,27 correcting for pos-
sible bias as a result of small sample sizes,28 was used as
the standardized between-group ES. Whenever possible,
ESs were computed using means and their standard de-
viations for preintervention, postintervention, or change
scores. If unavailable, ESs were estimated on the basis of
other reported statistics—for example, P values, F values,
or B values. Pooled ESs were weighted by the inverse SE,
taking into account the precision of each study. The N used
in the calculation was the N in the ﬁnal analysis. A random
effects model was chosen for all analyses, with positive
values indicating ESs in the hypothesized direction. If
studies reported results for more than one measure per
outcome, the independence of results was ensured by
averaging ESs across all outcomes so that only one result
per study was used for each quantitative data synthesis.
Heterogeneity
Heterogeneity was explored using Q and I2 statistics.29
Because of the generally low statistical power of hetero-
geneity tests, a more liberal P value of # .10 was used to
determine signiﬁcant heterogeneity.30 The I2 statistic is an
estimate of the variance in a pooled ES that is accounted for
by heterogeneity in the sample of studies and is unaffected
by the number of studies (K).31 I2 values of 0%, 25%, 50%,
and 75% are taken to indicate no, low, moderate, and high
heterogeneity, respectively.
Publication Bias
Positive and negative ﬁndings are not equally likely to be
published, and publication bias is a widespread problem
when reviewing available evidence.32 We evaluated pub-
lication bias using funnel plots and Egger’s test.33-35 If re-
sults indicated possible publication bias, adjusted ESs were
calculated using the Duval and Tweedie trim-and-ﬁll
method.36 In the case of statistically signiﬁcant results, we
calculated the failsafe number33,37 —that is, the number of
unpublished studies with null ﬁndings that would reduce
the results to statistical nonsigniﬁcance (P . .05)—and
evaluated the robustness of results by comparing the
failsafe number with the suggested criterion (5K + 10).37
Risk of Bias Assessment
We adapted the Cochrane Collaboration tool38 to evaluate
the risk of bias within the context of psychological in-
tervention studies. We included the original domains of
“random sequence allocation”, “allocation concealment”,
“blinding of outcome assessment”, “accounting for attri-
tion”, and “selective reporting”. We further differentiated
“other sources of bias” with three subdomains: “treatment
integrity” (ie, therapist training and ﬁdelity), “conﬂict of
interest” (ie, the trial was conducted by the therapists and/
or the original developers of the therapy), and “bias in
sampling and dropout” (eg, convenience sampling and
uneven dropouts in intervention and control groups). Two
authors (L.S. and G.O.) performed ratings independently.
Disagreements were discussed with a third author (N.T.)
until a negotiated ﬁnal rating was reached for each study.
Before the negotiation of a ﬁnal rating, independent ratings
were subjected to inter-rater reliability analyses (inter-rater
agreement and k statistics).39 Risk of bias scores were
calculated for each study by evaluating the risk of bias for
every item above as low, unclear (or not applicable), or high
risk, rated as 0, 1, and 2, respectively. Associations be-
tween ESs and risk of bias scores were explored using
meta-regression. Risk of bias scores were not used as
weights when calculating aggregated ESs, as this is dis-
couraged because of the risk of inducing bias.40
Analytical Strategy
OTs and noninferiority trials were descriptively reviewed,
and controlled trials (CTs) were subjected to meta-analysis
to determine the pooled overall ES. Pooled ESs from
baseline to post-treatment results and follow-up results
were calculated separately. If multiple follow-up assess-
ments were included, the longest follow-up assessment
was chosen. Moderation analyses were performed with
meta-regression on the basis of random-effects models and
were estimated using the maximum likelihood method
when data were available for 10 or more studies. Analyses
were conducted using Comprehensive Meta-Analysis ver-
sion 3 (http://www.meta-analysis.com).
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system41 to rate the
quality of evidence of the meta-analytic results. Quality of
evidence was graded as high, moderate, low, or very low.
GRADE uses a baseline rating of high for RCTs and low for
non-RCTs. This rating can be downgraded or upgraded on
the basis of eight assessment criteria, including risk of bias,
inconsistency of results, indirectness, imprecision, publi-
cation bias, effect magnitude, dose-response gradient, and
the effect of all plausible confounding factors that would
reduce the effect or suggest a spurious effect when no
effect is found. Ratings were conducted and negotiated by
two authors (M.S.O. and R.Z.).
RESULTS
The study selection process with reasons for exclusion
is described in Figure 1 and the Data Supplement.
The literature search yielded 1,394 references, of which
32 independent studies were subjected to descriptive
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evaluation. Of these, 23 CTs were subjected to meta-
analytic evaluation.
CT Characteristics
Study characteristics are listed in Table 1. The 23 CTs
included a total of 2,965 patients with a mean sample size
of 129.42-60,62-64 Of these, 21 studies reported post-
treatment data, with 16 of these reporting relevant
follow-up data. Two additional studies reported long-term
(follow-up) data only. Post-treatment data were analyzed for
2,163 participants. Follow-up data were obtained 29 weeks
on average after intervention and were analyzed for 2,044
participants. Most studies were RCTs (K = 21), with most
control groups receiving no therapist attention (K = 19). Of
the eight studies with FCR as the primary target of the
intervention, FCR severity was an inclusion criterion in four
studies only. All but one study were conducted in Western
countries, participants were predominantly white, and, in
most studies, the majority of participants were women (K =
21). Breast cancer was the most frequent cancer diagnosis
(K = 15) and, in themajority of studies (K = 18), participants
had no evidence of disease.
The 23 CTs evaluated a total of 25 interventions. Ten in-
terventions used a traditional cognitive behavioral therapy
(CBT) framework and nine interventions were contempo-
rary CBTs. Studies were categorized as traditional CBT
when interventions adhered to traditional cognitive be-
havioral principles that focus not only on Beckian therapy,
but also on cognitive therapy principles that rely on in-
formation processing models in which the individual is
assumed to hold biases, which gives rise to dysfunctional
thoughts and beliefs.73,74 Contemporary CBTs were deﬁned
as interventions that were focused on the processes, rather
than the content of cognition—for example, worry, rumi-
nation, attentional bias, and cognitive fusion—and aimed to
change the way in which the individual related to his or her
inner experiences.75-77 The remaining six interventions—
other interventions—varied too much to be meaningfully
grouped (eg, as psychodynamic therapy or supportive
therapy). Approximately one half of interventions were
group based (K = 13), with the remaining using an indi-
vidual format (K = 12). In most studies, interventions were
delivered face to face (K = 19). Number of sessions ranged
from one to 15 (mean, 6.6). Reducing FCR was the primary
aim in eight studies only.
OT Characteristics
Nine OTs were eligible for descriptive evaluation (Table 1).
All studies were described as feasibility or pilot studies and
had sample sizes that ranged from eight to 56 (mean,
29.1). FCR severity was the inclusion criterion in three
studies. Samples included prostate, breast, ovarian, and
mixed types of cancer, with participants in three studies
having current cancer. Five interventions could be cate-
gorized as traditional CBTs and the remaining four as
contemporary CBTs. Five interventions had a primary aim
of reducing FCR. Intervention was delivered in groups in
four studies, all but three interventions were delivered face
to face, and the number of sessions ranged from one to 10
(mean, 5.7). Eight studies reported positive statistically
signiﬁcant small-to-large within-subject ESs (range:
Hedges’s g = 0.33-3.15).18,65-67,69,71,72 The remaining study
Records identified
through other sources
(n = 10)
Records identified in databases
(n = 1,384)
Records screened after
duplicates removed
(n = 926)
Full-text articles assessed
for eligibility
(n = 103)
Independent studies included
in descriptive evaluation
(n = 32)
Studies excluded from
meta-analysis
(n = 9)
Studies included
in meta-analysis
(n = 23)
Records excluded
(n = 823)
(n = 39)
(n = 26)
(n = 3)
(n = 2)
(n = 1)
Records excluded                       (n = 71)
   Gray literature
   FCR not an outcome
   Language other than English
   Overlap with included paper
   Design not relevant
FIG 1. Study selection ﬂowchart. FCR, fear
of cancer recurrence.
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TABLE 2. Pooled Postintervention and Follow-Up Effects of Psychological Interventions on Fear of Cancer Recurrence Among Survivors of
Cancer
Effect
Sample
Size Heterogeneity* Global Effect Size
Failsafe No.‡ Criterion§K No. Q df P I2 Hedges’s g† 95% CI P
Postintervention
Overall combined effect 21k 2,163 38.9 20 .007 48.6 0.33 0.20 to 0.46 , .001 255 115
Cancer type: breast 12 1,067 24.2 11 .012 54.5 0.34 0.14 to 0.53 .010 64 70
Cancer type: other/mixed 9 1,096 14.4 8 .071 44.6 0.32 0.15 to .49 , .001 54 55
Cancer present 5 659 9.4 4 .050 57.8 0.27 0.03 to 0.52 .031 9 35
Disease free 16 1,504 26.6 15 .032 43.6 0.35 0.21 to 0.50 , .001 150 90
Study design: RCT 19 1,848 30.6 18 .032 41.2 0.33 0.20 to 0.46 , .001 200 105
Study design: CT 2 315 6.5 1 .011 84.7 0.36 20.30 to 1.02 .283 — —
Format: individual 9 949 14.7 8 .066 45.5 0.28 0.09 to 0.47 .003 29 55
Format: group 12 1,214 24.1 11 .012 54.4 0.37 0.19 to 0.55 , .001 98 70
Delivery: face to face 18 1,835 32.6 17 .013 47.9 0.38 0.24 to 0.51 , .001 234 110
Delivery: other 3 328 3.1 2 .204 37.2 0.10 20.19 to 0.38 .510 — —
FCR as primary target 8 908 20.0 7 .006 65.0 0.44 0.20 to 0.67 , .001 68 50
FCR as secondary target 13 1,255 18.0 12 .116 33.3 0.26 0.12 to 0.41 , .001 50 75
FCR level as inclusion criterion 4 544 8.9 3 .030 66.5 0.36 0.09 to 0.64 .010 13 30
FCR level not inclusion criterion 17 1,641 28.8 16 .025 44.5 0.32 0.17 to 0.46 , .001 137 95
Therapy: traditional CBT 9 1,025 11.7 8 .116 31.5 0.24 0.08 to 0.39 .003 25 55
Therapy: contemporary CBT 9 848 6.1 8 .642 0.0 0.42 0.29 to 0.56 , .001 66 55
Therapy: other 3 290 15.0 2 .001 86.6 0.35 20.32 to 1.02 .310 — —
FCR measure: CARS 6 792 13.4 5 .020 62.7 0.38 0.15 to 0.61 .001 28 40
FCR measure: FCRI 7 659 8.3 6 .216 27.8 0.33 0.10 to 0.55 .005 22 45
Follow-up
Overall combined effect 18 2,044 26.8 17 .061 36.6 0.28 0.17 to 0.40 , .001 158 100
Cancer type: breast 11 1,109 13.9 10 .176 28.2 0.36 0.20 to 0.52 , .001 77 65
Cancer type: other/mixed 7 936 10.9 6 .091 45.1 0.20 0.02 to 0.37 .031 9 45
Cancer present 5 612 10.1 4 .039 60.3 0.16 20.11 to 0.43 .235 — —
Disease free 13 1,432 15.1 12 .235 20.1 0.33 0.20 to 0.45 , .001 107 75
Study design: RCT 16 1,769 27.8 16 .034 42.4 0.29 0.15 to 0.43 , .001 100 90
Study design: CT 2 413 0.8 1 .386 0.0 0.43 0.22 to 0.64 , .001 — —
Format: individual 8 1,121 6.7 7 .463 0.0 0.19 0.07 to 0.31 .002 17 50
Format: group 10 923 15.8 9 .072 42.9 0.36 0.18 to 0.55 , .001 59 60
Delivery: face to face 14 1,417 25.8 13 .018 49.7 0.31 0.15 to 0.47 , .001 96 80
Delivery: other 4 627 0.4 3 .933 0.0 0.23 0.07 to 0.38 .006 4 30
FCR as primary target 8 1,135 14.0 7 .051 50.1 0.36 0.19 to 0.54 , .001 68 50
FCR as secondary target 10 910 9,6 9 .387 5.9 0.19 0.01to 0.33 .009 11 60
FCR level as inclusion criterion 2 362 0.4 1 .505 0.0 0.43 0.24 to 0.62 , .001 — —
FCR level not inclusion criterion 16 1,683 23.3 15 .079 35.5 0.26 0.12 to 0.39 , .001 88 90
Therapy: traditional CBT 7 1,025 11.1 6 .086 45.8 0.22 0.04 to 0.40 .015 17 45
Therapy: contemporary CBT 8 744 2.6 7 .902 0.0 0.30 0.16 to 0.45 , .001 20 50
(continued on following page)
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found no statistically signiﬁcant effect (g = 0.15; P = .44; no
additional data shown).70
Main Effects
Results of the meta-analyses are listed in Table 2 and il-
lustrated with forest plots in Figure 2 and the Data Sup-
plement. The overall combined postintervention ES was
statistically signiﬁcant and of small magnitude (g = 0.33;
95% CI, 0.20 to 0.46; P, .001). There were no indications
of publication bias, and the failsafe number for effects at
post-treatment (failsafe n = 255) exceeded the criterion
(n = 115), which suggested a robust result. The overall
combined effect at follow-up was statistically signiﬁcant and
only slightly smaller than at postintervention (g = 0.28; P,
.001). Again, there were no indications of publication bias,
and follow-up results seemed to be robust.
Heterogeneity
Statistically signiﬁcant Q tests and moderate I2 values for
both postintervention (48.6%) and follow-up results (36.6%;
Table 2) suggested some degree of variability in ESs
beyond sampling error.
Subgroup and Moderation Analyses
As shown in Table 2, when examining the results of the
prespeciﬁed study subgroups—categorized according to
cancer type, disease status, study design, format, delivery,
FCR as primary or secondary target, FCR level as inclusion
criterion or not, and psychotherapeutic framework—ESs
were, with few exceptions, generally comparable across
subgroups of studies. Almost all ESs were of small mag-
nitude at both postintervention and follow-up. Results of the
meta-regression analyses are listed in Table 3. At post-
intervention, effects of contemporary CBTs (g = 0.42) were
larger than those of traditional CBTs (g = 0.24; b = .22; P =
.018). At follow-up, larger effects were associated with
shorter time to follow-up (in weeks; b =2.01; P = .027) and
with group-based format compared with individual treat-
ment format (b = .18; P = .041; Data Supplement).
Changes in raw scores for the two most frequently used
FCR measures—Concerns About Recurrence Scale and
Fear of Cancer Recurrence Inventory—corresponded to
mean differences of 1.3 (95% CI, 0.4 to 2.3; Concerns
About Recurrence Scale overall fear) and 2.2 (95% CI,
1.4 to 3.1; Fear of Cancer Recurrence Inventory severity
subscale; Data Supplement).
Risk of Bias
Before negotiation, the two raters (L.S. and G.O.) agreed
on 150 (81.5%) of 184 risk of bias ratings, and the inter-
rater agreement (k39) for the individual domains ranged
from almost perfect (0.91; random sequence allocation)
to fair (0.39; treatment integrity). Final negotiated results
of risk of bias assessments for each study are shown in
Figure 3 (for additional details, see the Data Supplement).
No associations were found between total risk of bias
scores and ESs at postintervention and follow-up
(Table 3).
Overall Quality of Meta-Analytic Evidence
The overall evidence for RCTs was qualiﬁed using
GRADE.41 Overall, moderate quality of evidence demon-
strates that psychological intervention may reduce FCR
symptom compared with control conditions. The level of
evidence for RCTs was downgraded to moderate as a result
of concerns regarding inconsistency—that is, methodo-
logic and clinical heterogeneity and inability to identify the
reasons for heterogeneity—and indirectness—that is, that
a considerable proportion of studies (K = 13) had FCR as
secondary outcome, most studies included women only,
and the majority of studies focused on FCR in cancer
survivors, not fear of progression in patients with cancer
TABLE 2. Pooled Postintervention and Follow-Up Effects of Psychological Interventions on Fear of Cancer Recurrence Among Survivors of
Cancer (continued)
Effect
Sample
Size Heterogeneity* Global Effect Size
Failsafe No.‡ Criterion§K No. Q df P I2 Hedges’s g† 95% CI P
Therapy: other 3 276 11.4 2 .003 82.4 0.54 20.08 to 1.16 .088 — —
FCR measure: CARS 7 1,086 19.7 6 .003 69.5 0.34 0.10 to 0.57 .005 35 45
FCR measure: FCRI 4 382 1.1 3 .775 0.0 0.22 0.02 to 0.42 .031 0 30
Abbreviations: CARS, Concerns About Recurrence Scale; CBT, cognitive behavioral therapy; CT, controlled trial; FCR, fear of cancer
recurrence; FCRI, Fear of Cancer Recurrence Inventory; RCT, randomized controlled trial.
*Q-statistic: P values , .1 are taken to suggest heterogeneity. I2 statistic: 0% (no heterogeneity), 25% (low heterogeneity), 50% (moderate
heterogeneity), and 75% (high heterogeneity).
†Effect size: Hedges’s g. A positive value indicates an effect size in the hypothesized direction. All effect sizes were combined using a random
effects model. Conventions: small (0.2), medium (0.5), or large (0.8).27
‡Number of nonsigniﬁcant studies that would bring the P value to nonsigniﬁcant (P . .05).
§A failsafe number that exceeds the criterion (5 3 K + 10) indicates a robust result.37
kK , 23, as two studies did not assess outcomes at postintervention.
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present. Overall, no serious concerns were found for risk of
bias, imprecision, and publication bias.
DISCUSSION
The primary objective of the current study was to evaluate
the efﬁcacy of psychological interventions in alleviating FCR
symptoms among patients with and survivors of cancer.
Twenty-three controlled studies were identiﬁed, revealing
a statistically signiﬁcant effect on FCR outcomes of a small
magnitude (g = 0.33) immediately after intervention, which
was largely maintained at follow-up (g = 0.28), on average
more than 7 months after the intervention. Results were
robust with no indications of publication bias, which sup-
ported our hypothesis that psychological interventions
would be efﬁcacious relative to controls in reducing FCR
symptoms. These ﬁndings are encouraging, given that
managing FCR is a common unmet need among survivors
of cancer6 and, when persistent and excessive, leaves the
individual at risk of depression, impaired daily functioning,
using unnecessary health assessments, and reduced
quality of life.1,2 Furthermore, current ﬁndings point to
lasting effects of FCR interventions beyond the immediate
completion of the intervention. This ﬁnding is particularly
relevant, as unmanaged FCR tends to stabilize over time.2,7
Here, it should be noted that follow-up times varied from
6 weeks to 78 weeks across studies and that meta-
regression demonstrated that longer time to follow-up as-
sessment was associated with a statistically signiﬁcantly
smaller effect. Number of sessions ranged from one to 15,
with an average of 6.6 sessions, but no associations were
found between the number of sessions and ES either at
postintervention or at follow-up.
A secondary aim was to explore the possible inﬂuence
of between-study differences. The larger effect found at
postintervention for contemporary CBTs (g = 0.42) com-
pared with traditional CBTs (g = 0.24) supports a hypothesis
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0.57 (-0.06 to 1.20)
0.11 (-0.14 to 0.37)
0.54 (0.12 to 0.97)
-0.13 (-1.11 to 0.85)
0.06 (-0.15 to 0.27)
0.26 (-0.16 to 0.68)
0.57 (0.10 to 1.04)
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0.49 (0.05 to 0.92)
0.16 (-0.39 to 0.71)
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0.31 (-0.16 to 0.77)
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FIG 2. Forest plot of effect sizes (ESs; Hedges’s g) for effects at postintervention of psychological interventions on fear of cancer recurrence (FCR).
(*) Weights are from random effects analysis.
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that FCR may be particularly responsive to contemporary
therapies that aim to change the way in which individuals
relate to their inner experiences by focusing on cognitive
processing and metacognitions in FCR—for example,
worry, rumination, or attentional bias.78,79 The difference no
longer reached statistical signiﬁcance at follow-up, mainly
because of smaller ESs of contemporary CBTs at follow-up,
which perhaps suggests that meta-cognitive skills learned
in contemporary CBTs require booster sessions or materials
to maintain long-term effects. Larger effects at follow-up
were associated with shorter time to follow-up and with
a group-based format compared with an individual treat-
ment format. We have no clear explanation for the latter
ﬁnding, which could be explored in future research.
All remaining moderation analyses failed to reach statistical
signiﬁcance. It has previously been found that newly di-
agnosed patients with cancer and younger survivors are
more prone to experiencing high levels of FCR,2 but neither
the presence of cancer, nor age was associated with overall
intervention effect. Given the relatively small number of
studies in the moderation analyses, which likely compro-
mised our statistical power, two results should be noted
when considering the numerical difference in ESs. First, the
ES obtained at post-treatment with treatment delivered face
to face was numerically larger (g = 0.38) than treatments
that were delivered by other means (eg, telephone or Web
based; g = 0.10). Only three studies used such other
delivery means and results should be interpreted accord-
ingly; the small number of studies demonstrated that
delivery methods other than traditional face-to-face treat-
ments are largely unexplored within the context of FCR.
Internet-based interventions have previously been shown to
be effective for anxiety disorders and fear-related condi-
tions80 and have obtained equivalent effects to face-to-face
treatments.81 It remains a question of whether this could be
the case for FCR as well. Second, studies with FCR as their
primary target obtained larger ESs at both postintervention
TABLE 3. Moderators of Effects at Postintervention and Follow-Up: Results of Meta-Regression Analyses
Moderator K b* 95% CI P (two tailed)
Postintervention
Cancer type: breast (referent: other) 21 0.01 20.24 to 0.25 .969
FCR primary target (referent: secondary) 21 0.15 20.10 to 0.39 .255
FCR level inclusion criterion (referent: not a criterion) 21 0.04 20.25 to 0.33 .788
Format: group (referent: individual) 21 0.09 20.16 to 0.34 .477
Delivery: face to face (referent: other) 21 0.28 20.05 to 0.60 .094
Therapy: contemporary CBT (referent: traditional CBT) 18 0.22 0.04 to 0.41 .018
Gender: percent women in sample (range, 0% to 100%) 21 0.00 20.01 to 0.01 .882
Time to postintervention assessment, weeks (range, 2-26) 21 20.01 20.03 to 0.01 .327
No. of sessions (range, 1-15) 21 0.01 20.03 to 0.04 .673
Mean sample age, years (range, 44-70) 21 0.00 20.03 to 0.03 .911
Risk of bias score (range, 1-13) 21 20.01 20.04 to 0.04 .984
FCR measure: CARS (referent: FCRI) 13 0.04 20.25 to 0.34 .766
Follow-up
Cancer type: breast (referent: other) 18 0.15 20.06 to 0.37 .162
FCR primary target (referent: secondary) 18 0.16 20.04 to 0.36 .115
FCR level inclusion criterion (referent: not a criterion) 18 0.18 20.05 to 0.42 .124
Format: group (referent: individual) 18 0.18 0.01 to 0.36 .041
Delivery: face to face (referent: other) 18 20.07 20.31 to 0.17 .551
Therapy: contemporary CBT (referent traditional CBT) 15 0.07 20.13 to 0.28 .486
Gender: percent women in sample (range, 0% to 100%) 18 0.00 20.01 to 0.01 .377
Time to follow-up assessment, weeks (range, 6-78) 14 20.01 20.01 to 20.00 .027
No. of sessions (range, 1-12) 17 20.02 20.07 to 0.03 .435
Mean sample age, years (range, 44-70) 18 20.01 20.03 to 0.01 .522
Risk of bias score (range, 1-13) 18 0.02 20.01 to 0.06 .130
FCR measure: CARS (referent: FCRI) 11 0.10 20.23 to 0.43 .566
Abbreviations: CARS, Concerns About Recurrence Scale; CBT, cognitive behavioral therapy; FCR, fear of cancer recurrence; FCRI, Fear of
Cancer Recurrence Inventory.
*Maximum likelihood method.
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and follow-up (g = 0.42; 0.36) than studies examining
FCR as a secondary target (g = 0.26; 0.19). This ﬁnding
should be further explored as the number of treatment
studies increases, sufﬁciently powering analyses to test
whether treatments with FCR as their primary target are
superior in reducing FCR symptoms compared with
generalized interventions. In addition, only four studies
included participants on the basis of their FCR symptom
levels and it is unclear to what degree this may have
inﬂuenced results.
Robust but relatively small effects point to a number of
potential implications, both clinically and for future research.
Establishing the efﬁcacy of psychological interventions for
FCR should also concern which treatment components may
be most efﬁcacious or which processes drive the effect.
Fardell et al78 have suggested a number of key maintaining
processes of FCR, resulting in a theoretical model with
dysfunctional cognitive processes at its core. The authors
suggest that particular treatment components from con-
temporary CBTs, including metacognitive therapy82 and
acceptance and commitment therapy,83 are well suited for
targeting such processes. Future treatment trials should not
only establish the efﬁcacy of their treatment, but also in-
vestigate which components are most change potent. One
approach could be the Multiphase Optimization Strategy,84
a systematic method for exploring the main and interactive
effects of treatment components and investigating select
treatment components in a factorial design where all pos-
sible combinations of components are evaluated. Further-
more, the dose needed for effective treatment of FCR is likely
not identical for all individuals and intervention researchers
are increasingly interested in ways to individually tailor
psychotherapy (eg, Fisher and Boswell).85 Existing therapies
already suggest conducting a thorough individual case
formulation58; however, to date, treatment programs for FCR
have not outlined or investigatedmarkers—for example, time
since diagnosis, severity of FCR, or level or type of dys-
functional cognitive processes—suggestive of including or
abandoning certain treatment components or increasing or
decreasing the dose. Theoretical formulations of FCR78
could guide researchers in identifying relevant markers to
investigate.
Our results should be viewed in light of limitations that
pertain to the methodology of the included studies and
between-study heterogeneity, noting that overall strength of
the evidence was downgraded to moderate. Many studies
suffered from the risk of selective reporting. Although
evaluating the effect within the different categories pertaining
to each of the identiﬁed moderators, between-study het-
erogeneity for most categories remained moderate to large.
This could indicate potentially unidentiﬁed variables that are
responsible for systematic variation. Finally, it should be
noted that all but four authors have contributed to the
studies included in the present review, which might raise
concerns regarding bias. However, this may be less of an
issue as the review was preregistered; all authors agreed to
the ﬁnal protocol; the ﬁrst, second, and corresponding
authors (N.M.T., M.S.O., and R.Z.) have not yet published
any intervention studies on FCR; and screening and data
extraction was performed by authors who had not been
principle investigators of any of the reviewed studies.
In conclusion, to our knowledge, this is currently the most
comprehensive systematic review and meta-analysis of the
effect of controlled psychological intervention studies
speciﬁcally on FCR outcomes. Twenty-three CTs were lo-
cated, revealing a statistically signiﬁcant effect on FCR
outcomes of a small magnitude that was largely maintained
at follow-up. Psychological interventions therefore seem to
be efﬁcacious in reducing FCR symptoms. Future trials
should focus on targeted interventions for FCR, include
participants on the basis of high levels of FCR, and in-
vestigate how to further optimize interventions—for in-
stance, by exploring the effect of different treatment
components and tailoring the intervention to the in-
dividual’s FCR symptoms.
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FIG 3. Risk of bias. Blue box with
plus sign indicates a low risk of bias;
red box with question mark indicates
an unclear risk of bias; teal box with
minus sign indicates a high risk of
bias. N/A, not applicable.
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